The FDA on November 20, 2015 approved MEKINIST® and TAFINLAR® for use in combination, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. MEKINIST® and TAFINLAR® are products of Novartis Pharmaceuticals Corp.